Dishman Carbogen Amcis Limited - Asset Resilience Ratio
Dishman Carbogen Amcis Limited (DCAL) has an Asset Resilience Ratio of 5.68% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Dishman Carbogen Amcis Limited for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2025)
This chart shows how Dishman Carbogen Amcis Limited's Asset Resilience Ratio has changed over time. See Dishman Carbogen Amcis Limited (DCAL) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Dishman Carbogen Amcis Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Dishman Carbogen Amcis Limited (DCAL) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs6.16 Billion | 5.54% |
| Short-term Investments | Rs157.30 Million | 0.14% |
| Total Liquid Assets | Rs6.31 Billion | 5.68% |
Asset Resilience Insights
- Limited Liquidity: Dishman Carbogen Amcis Limited maintains only 5.68% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Dishman Carbogen Amcis Limited Industry Peers by Asset Resilience Ratio
Compare Dishman Carbogen Amcis Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Dishman Carbogen Amcis Limited (2005–2025)
The table below shows the annual Asset Resilience Ratio data for Dishman Carbogen Amcis Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 0.35% | Rs354.30 Million ≈ $3.83 Million |
Rs99.99 Billion ≈ $1.08 Billion |
-1.42pp |
| 2024-03-31 | 1.77% | Rs1.70 Billion ≈ $18.38 Million |
Rs95.81 Billion ≈ $1.04 Billion |
-0.62pp |
| 2023-03-31 | 2.40% | Rs2.26 Billion ≈ $24.49 Million |
Rs94.53 Billion ≈ $1.02 Billion |
-1.59pp |
| 2022-03-31 | 3.98% | Rs3.44 Billion ≈ $37.22 Million |
Rs86.37 Billion ≈ $934.11 Million |
+1.74pp |
| 2021-03-31 | 2.24% | Rs1.88 Billion ≈ $20.29 Million |
Rs83.66 Billion ≈ $904.76 Million |
+0.60pp |
| 2020-03-31 | 1.64% | Rs1.35 Billion ≈ $14.57 Million |
Rs82.00 Billion ≈ $886.78 Million |
+1.00pp |
| 2019-03-31 | 0.64% | Rs471.10 Million ≈ $5.09 Million |
Rs73.28 Billion ≈ $792.55 Million |
-1.08pp |
| 2018-03-31 | 1.73% | Rs1.24 Billion ≈ $13.40 Million |
Rs71.76 Billion ≈ $776.11 Million |
+1.42pp |
| 2017-03-31 | 0.30% | Rs199.20 Million ≈ $2.15 Million |
Rs65.93 Billion ≈ $713.05 Million |
+0.18pp |
| 2016-03-31 | 0.12% | Rs36.30 Million ≈ $392.57K |
Rs29.81 Billion ≈ $322.33 Million |
-0.35pp |
| 2015-03-31 | 0.47% | Rs132.00 Million ≈ $1.43 Million |
Rs28.13 Billion ≈ $304.22 Million |
+0.47pp |
| 2013-03-31 | 0.00% | Rs117.00K ≈ $1.27K |
Rs23.15 Billion ≈ $250.35 Million |
-0.20pp |
| 2012-03-31 | 0.21% | Rs46.13 Million ≈ $498.86K |
Rs22.49 Billion ≈ $243.22 Million |
-0.07pp |
| 2011-03-31 | 0.27% | Rs56.35 Million ≈ $609.41K |
Rs20.82 Billion ≈ $225.19 Million |
+0.27pp |
| 2008-03-31 | 0.00% | Rs-1.00K ≈ $-10.81 |
Rs14.70 Billion ≈ $158.94 Million |
-0.36pp |
| 2005-03-31 | 0.36% | Rs11.65 Million ≈ $126.00K |
Rs3.22 Billion ≈ $34.84 Million |
-- |
About Dishman Carbogen Amcis Limited
Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical and healthcare industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It offers cholesterol and vitamin D analogs; generic active pharmaceutical ingredients for diagnostics, ophthalmic treatments, laxatives, organop… Read more